Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received an average rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and three have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $35.00.

A number of research firms have recently weighed in on DYN. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. HC Wainwright dropped their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, Morgan Stanley dropped their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $17.04 on Monday. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -5.29 and a beta of 1.09. The company has a 50 day moving average of $18.28 and a two-hundred day moving average of $18.26. Dyne Therapeutics has a 52-week low of $8.06 and a 52-week high of $25.00. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the previous year, the business posted ($1.05) EPS. As a group, analysts forecast that Dyne Therapeutics will post -3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Erick Lucera sold 1,448 shares of Dyne Therapeutics stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $26,585.28. Following the completion of the sale, the chief financial officer owned 123,925 shares in the company, valued at approximately $2,275,263. The trade was a 1.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Douglas Kerr sold 1,564 shares of Dyne Therapeutics stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $28,715.04. Following the completion of the transaction, the insider directly owned 170,042 shares of the company’s stock, valued at approximately $3,121,971.12. This represents a 0.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have purchased 7,000 shares of company stock valued at $122,920 and have sold 1,559,462 shares valued at $29,814,746. 9.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DYN. T. Rowe Price Investment Management Inc. boosted its holdings in Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period. Orbis Allan Gray Ltd acquired a new position in Dyne Therapeutics in the fourth quarter worth $93,926,000. Adage Capital Partners GP L.L.C. acquired a new position in Dyne Therapeutics in the second quarter worth $30,378,000. Perceptive Advisors LLC boosted its holdings in Dyne Therapeutics by 543.7% in the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after purchasing an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP boosted its holdings in Dyne Therapeutics by 572.9% in the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.